期刊
CURRENT OPINION IN PULMONARY MEDICINE
卷 21, 期 6, 页码 626-633出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MCP.0000000000000217
关键词
common epigenetic marks in idiopathic pulmonary fibrosis and cancer; epigenetics; idiopathic pulmonary fibrosis; lung cancer
资金
- Department of Thoracic Medicine, University Hospital of Heraklion, Crete, Greece
- Department of Diseases of the Thorax, Pulmonary Unit, GB Morgagni Hospital, Forli, Italy
- Regional Center for Interstitial and Rare Lung Diseases, Department of Clinical and Experimental Medicine, University Hospital Policlinico-Vittorio Emanuele, Catania, Italy
Purpose of review About one out of 10 patients with idiopathic pulmonary fibrosis (IPF) develop lung cancer. This review provides an epidemiology and clinical update of the association of these two lethal diseases. In addition, we focus on the emerging overlapping epigenetic mechanisms in both diseases. Recent findings In a vast majority of cases, lung cancer is diagnosed during the clinical and radiological follow-up for the fibrosis. The risk of development of lung cancer in IPF is higher for older male smokers and there is a significantly higher prevalence of lung cancer in the combined IPF and emphysema syndrome compared with fibrosis only. The association of two lethal diseases, such as IPF and lung cancer, carries a very poor outcome and the correct treatment strategy, particularly for advanced forms of lung cancer, is still unclear. Summary The two novel drugs approved for IPF, pirfenidone and nintedanib, open a new scenario in which treated patients with fibrosis will live longer, and possibly have a lower incidence of lung cancer. However, prospective studies are urgently needed to definitively clarify the role of lung cancer treatment in the management of IPF patients. Furthermore, common epigenetic alterations may represent a promising target for therapeutic approaches in the near future.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据